Exclusive: Cigna ends employee coverage for GLP‑1 weight drugs

• Coverage ends July 1 for GLP-1 drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound
• The decision affects Cigna's own employee health plan (Cigna Group Medical Plan)
• Cigna will maintain alternative weight management programs and resources for employees

Summary

Health insurer Cigna will discontinue coverage of GLP-1 weight-loss medications, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, under its employee health plan effective July 1. The decision was announced in internal materials viewed by Reuters and confirmed by a Cigna spokesperson.

Key Companies: Cigna Group, Novo Nordisk, Eli Lilly

Products Affected: GLP-1 weight-loss drugs (Wegovy, Zepbound)

Rationale: Cigna cited increased availability and emerging alternatives as reasons for ending coverage. The company stated it will continue supporting employee health through alternative weight management programs and resources.

Market Implications:

This move by a major health insurer signals potential challenges for GLP-1 drugmakers, particularly as the weight-loss medication market expands. The decision could reflect growing cost concerns among employers and insurers regarding these expensive treatments. While Cigna's employee plan represents a relatively small segment, the policy change may influence broader industry coverage decisions.

The announcement comes as demand for GLP-1 medications has surged, with these drugs becoming blockbuster products for both Novo Nordisk and Eli Lilly. Any reduction in insurance coverage could impact market growth projections and accessibility for patients seeking these treatments for weight management.

Timeline: Coverage ends July 1

The decision underscores ongoing debates about the cost-benefit analysis of covering weight-loss medications in employer health plans, despite their clinical effectiveness and popularity.